Evidence map›Paper›PMID 39423870›Full record

ArticleJournal of hepatology2025

Hyperfunctional T cell responses unchecked by regulatory T cells are unable to resolve hepaciviral infection without humoral contribution.

Fengzhi Jin, John Gridley, Anuradha Kumari, Alireza Saeidi, Brantley Holland, Elizabeth Elrod, Piyush Dravid, Sheetal Trivedi, Amit Kapoor, Manoj Thapa and 1 more

Abstract read
In one paragraph

Article in Journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Neonatal liver niches program T cell tolerance.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fengzhi JinEmory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
John GridleyEmory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Anuradha KumariEmory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Alireza SaeidiEmory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Brantley HollandEmory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Elizabeth ElrodEmory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Piyush DravidCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital and Department of Pediatrics, Ohio State University, Columbus, Ohio, USA.
Sheetal TrivediCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital and Department of Pediatrics, Ohio State University, Columbus, Ohio, USA.
Amit KapoorCenter for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital and Department of Pediatrics, Ohio State University, Columbus, Ohio, USA.
Manoj ThapaEmory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Arash GrakouiEmory National Primate Research Center, Emory University, Atlanta, Georgia, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: arash.grakoui@emory.edu.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 1985 to 2011
$114.0M
Protective immunity to HCV and rational vaccine designU19AI159819 · NIAID · EMORY UNIVERSITY · PI Arash Grakoui · 2021 to 2026
$16.6M
Training a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4M
Dynamics of antigen specific B and Tfh responses during acute and chronic HCVR01AI136533 · NIAID · EMORY UNIVERSITY · PI GRAKOUI, ARASH · 2018 to 2022
$3.8M
Immune correlates of protection against hepacivirus persistence.R01AI151175 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI KAPOOR, AMIT · 2021 to 2024
$2.5M
Animal Model to study heterogeneous outcomes of HCV Infection and PathogenesisR01AI183877 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Amit Kapoor · 2024 to 2026
$2.4M
Viral Determinants of Chronic Hepacivirus InfectionR01AI185926 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Amit Kapoor · 2024 to 2026
$2.0M
MyD88-dependent B cell dysfunction and autoimmunity during chronic liver diseaseK01DK109025 · NIDDK · EMORY UNIVERSITY · PI THAPA, MANOJ · 2017 to 2021
$505k
NCRR NIH HHS P51 RR000165NIAID NIH HHS R01 AI136533NIAID NIH HHS R01 AI151175NIAID NIH HHS R01 AI183877NIAID NIH HHS R01 AI185926NIAID NIH HHS T32 AI074492NIAID NIH HHS U19 AI159819NIDDK NIH HHS K01 DK109025NIH HHS P51 OD011132
6 · The paper itself

Abstract

BACKGROUND &

aimsThe most recent T cell-based vaccine against HCV tested in humans failed to swing the pendulum from chronicity to resolution, despite eliciting cellular responses in most individuals. These results naturally evoke the question of whether hyperactivated responses of a single adaptive immune arm are capable of inducing HCV clearance or if coordinated efforts between antibodies and T cells are indeed necessary. Here, we sought to address this point in determining whether the suppression of antiviral T cell and IgG responses by regulatory T cells (Tregs) is a critical prerequisite of delayed viral clearance or overt chronicity.

methodsUsing a surrogate model of HCV infection, rodent hepacivirus (RHV) infection in mice, we utilized Foxp3-DTR mice to assess how Tregs modulate the generation of acute antiviral adaptive immune responses and indirectly dictate infection fate via intracellular flow cytometry staining, ELISA, RNA sequencing, and qPCR.

resultsTransient depletion of Tregs prior to infection decreased viral-specific CD4

conclusionsTregs control the outcome of RHV infection via direct modulation of CD4 IMPACT AND IMPLICATIONS: Herein, we demonstrate how timing of regulatory T cell depletion determines the fate of effector T cells, humoral responses, and the kinetics of viral clearance. Our observations provide direct evidence that functional T cell responses are incapable of compensating for suboptimal humoral responses to facilitate viral resolution. Our results imply that future HCV vaccine regimens should not solely rely on eliciting focused responses of a single effector arm, but rather incorporate immunogens capable of inducing durable features of both humoral and cellular memory.

Indexed as

HepacivirusHepatitis CT-Lymphocytes, RegulatoryAnimalsDisease Models, AnimalImmunity, HumoralImmunoglobulin GMiceMice, Inbred C57BLImmunoglobulin GB cellsCD4(+) T cellsRat hepacivirusregulatory T cellsviral clearanceVirus-specific IgG

Identifiers

PMID39423870
PMCPMC11911089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.